These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2518869)

  • 1. Safety and efficacy of acetarsol suppositories in unresponsive proctitis.
    Forbes A; Britton TC; House IM; Gazzard BG
    Aliment Pharmacol Ther; 1989 Dec; 3(6):553-6. PubMed ID: 2518869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acetarsol Suppositories: Effective Treatment for Refractory Proctitis in a Cohort of Patients with Inflammatory Bowel Disease.
    Kiely CJ; Clark A; Bhattacharyya J; Moran GW; Lee JC; Parkes M
    Dig Dis Sci; 2018 Apr; 63(4):1011-1015. PubMed ID: 29457211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acetarsol in the management of mesalazine-refractory ulcerative proctitis: a tertiary-level care experience.
    Argyriou K; Samuel S; Moran GW
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):183-186. PubMed ID: 30499784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COMPARISON OF ACETARSOL AND PREDNISOLONE-21-PHOSPHATE SUPPOSITORIES IN THE TREATMENT OF IDIOPATHIC PROCTITIS.
    CONNELL AM; LENNARD-JONES JE; MISIEWICZ JJ; BARON JH; JONES FA
    Lancet; 1965 Jan; 1(7379):238. PubMed ID: 14238065
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of mesalamine 1 g HS versus 500 mg BID suppositories in mild to moderate ulcerative proctitis: a multicenter randomized study.
    Lamet M; Ptak T; Dallaire C; Shah U; Grace M; Spenard J; de Montigny D;
    Inflamm Bowel Dis; 2005 Jul; 11(7):625-30. PubMed ID: 15973115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis.
    Gionchetti P; Rizzello F; Venturi A; Ferretti M; Brignola C; Miglioli M; Campieri M
    Dis Colon Rectum; 1998 Jan; 41(1):93-7. PubMed ID: 9510317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. The Italian IBD Study Group.
    d'Albasio G; Paoluzi P; Campieri M; Bianchi Porro G; Pera A; Prantera C; Sturniolo GC; Miglioli M
    Am J Gastroenterol; 1998 May; 93(5):799-803. PubMed ID: 9625131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The usefulness of mesalazine suppositories for the treatment of lymphoid follicular proctitis].
    Seo GS; Choi SC; Jo EY; Choi CS; Kim JW; Kim TH; Yun KJ; Nah YH
    Korean J Gastroenterol; 2006 Jun; 47(6):420-4. PubMed ID: 16809948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acetarsol-induced Stevens-Johnson syndrome.
    Mohamed KN
    DICP; 1990 Jan; 24(1):99-100. PubMed ID: 2301196
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of new-onset ulcerative colitis and ulcerative proctitis: a retrospective study.
    Richter JM; Kushkuley S; Barrett JA; Oster G
    Aliment Pharmacol Ther; 2012 Aug; 36(3):248-56. PubMed ID: 22690748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rectal tacrolimus in the treatment of resistant ulcerative proctitis.
    Lawrance IC; Copeland TS
    Aliment Pharmacol Ther; 2008 Nov; 28(10):1214-20. PubMed ID: 18761706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical agents for idiopathic distal colitis and proctitis.
    Lawrance IC
    J Gastroenterol Hepatol; 2011 Jan; 26(1):36-43. PubMed ID: 21175791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative, open, randomized trial of the efficacy and tolerance of slow-release 5-ASA suppositories once daily versus conventional 5-ASA suppositories twice daily in the treatment of active cryptogenic proctitis: French Pentasa Study Group.
    Marteau P; Florent C
    Am J Gastroenterol; 2000 Jan; 95(1):166-70. PubMed ID: 10638577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using 99mTc-labeled 5-ASA suppositories.
    Williams CN; Haber G; Aquino JA
    Dig Dis Sci; 1987 Dec; 32(12 Suppl):71S-75S. PubMed ID: 3319461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis.
    Andus T; Kocjan A; Müser M; Baranovsky A; Mikhailova TL; Zvyagintseva TD; Dorofeyev AE; Lozynskyy YS; Cascorbi I; Stolte M; Vieth M; Dilger K; Mohrbacher R; Greinwald R;
    Inflamm Bowel Dis; 2010 Nov; 16(11):1947-56. PubMed ID: 20310020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimized Management of Ulcerative Proctitis: When and How to Use Mesalazine Suppository.
    Kato S; Ishibashi A; Kani K; Yakabi K
    Digestion; 2018; 97(1):59-63. PubMed ID: 29393142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consecutive monitoring of faecal calprotectin during mesalazine suppository therapy for active rectal inflammation in ulcerative colitis.
    Yamamoto T; Shimoyama T; Matsumoto K
    Aliment Pharmacol Ther; 2015 Sep; 42(5):549-58. PubMed ID: 26140337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi Matrix System Mesalazine Plus Rectal Mesalazine in the Treatment of Mild to Moderately Active Ulcerative Proctitis.
    Cuomo A; Sgambato D; D'Auria MV; Miranda A; Ferrante E; Romano M
    Dig Dis; 2018; 36(2):130-135. PubMed ID: 29339645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective randomized placebo-controlled double-blinded pilot study of misoprostol rectal suppositories in the prevention of acute and chronic radiation proctitis symptoms in prostate cancer patients.
    Khan AM; Birk JW; Anderson JC; Georgsson M; Park TL; Smith CJ; Comer GM
    Am J Gastroenterol; 2000 Aug; 95(8):1961-6. PubMed ID: 10950043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind comparison of 5-aminosalicylic acid and acetyl-5-aminosalicylic acid suppositories in patients with idiopathic proctitis.
    van Hogezand RA; van Hees PA; van Gorp JP; van Lier HJ; Bakker JH; Wesseling P; van Haelst UJ; van Tongeren JH
    Aliment Pharmacol Ther; 1988 Feb; 2(1):33-40. PubMed ID: 2979230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.